Evaluation of blood vessel ingrowth in fibrin gel subject to type and concentration of growth factors.
Our aim was to quantitatively assess the angiogenetic effects of VEGF and bFGF immobilized in a fibrin-based drug delivery system in a suitable subcutaneous rat model. After evaluation of a suitable implantation technique (6 rats), four teflon isolation chambers containing fibrin gel matrices were implanted subcutaneously in an upside-down fashion on the back of 30 Lewis rats. The matrices consisted of 500 microl fibrin gel with two different fibrinogen concentrations (10 mg/ml or 40 mg/ml fibrinogen) and 2 I.U./ml thrombin and contained VEGF and bFGF in five different concentrations (0 to 250 ng/ml each). At 3, 7 and 14 days after implantation, matrices were explanted and subjected to histological and morphometrical analysis. At 1 week, the volume of the fibrin clots was significantly smaller in the 100 and 250 ng/ml VEGF and bFGF groups in comparison to lower concentrated growth factors. At 1 and 2 weeks, the use of growth factors in low concentrations (25 ng/ml VEGF and bFGF) significantly increased the amount of fibrovascular tissue, average fraction of blood vessels and number of blood vessels at the matrix-host interface in comparison to growth factor-free controls. Higher concentrations were neither associated with further increase of tissue formation nor with increased sprouting of blood vessels in this model. This study demonstrates that fibrin gel-immobilized angioinductive growth factors efficiently stimulate generation of fibrovascular tissue and sprouting of blood vessels in a newly developed subcutaneous upside-down isolation chamber model with an optimum between 25 and 100 ng/ml.
Arkudas
A
A
Department of Plastic and Hand Surgery, University of Erlangen Medical Center, Erlangen, Germany.
Tjiawi
J
J
Saumweber
A
A
Beier
J P
JP
Polykandriotis
E
E
Bleiziffer
O
O
Horch
R E
RE
Kneser
U
U
D000818:Animals; D001808:Blood Vessels / Q000187:drug effects* / Q000254:growth & development*; D005337:Fibrin / Q000494:pharmacology*; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D005782:Gels; D008297:Male; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D019919:Prosthesis Implantation; D051381:Rats; D011917:Rats, Inbred Lew; D013194:Staining and Labeling; D042442:Vascular Endothelial Growth Factors / Q000494:pharmacology*
D005782:Gels; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D005337:Fibrin